Information about the Annual Report 2024/2025

Diamyd Medical today publishes its Annual Report for 2024/25. The Company is in an expansive phase where positive feedback has been received from the US Food and Drug Administration (FDA) regarding the possibility of earlier market approval. The Annual Report is published in Swedish. The English version is expected to be published around December 5, 2025.- The development in type 1 diabetes has never had greater momentum, supported by a regulatory environment increasingly favoring disease-modifying therapies. With the FDA's fast track and orphan drug designations for our investigational